ES
MARKETS / NASDAQ / LQDA
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Liquidia Corporation LQDA

7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$158.3M
▲ 1031.2% vs FY2024
EPS · FY25
$-0.80
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-111.1%
Net margin · FY25
-43.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 158.3M
Revenue, FY2025 · full 7-year series below
Revenue Net income
0.040.080.120.160.2-0.1201920222025
0.040.080.120.160.2-0.1201920222025

The company lost 44 cents on every revenue dollar this year.

Per share
USD -0.80
Diluted EPS, FY2025
EPS
0.40.81.2-0.80201920222025
0.40.81.2-0.80201920222025

The company pays no cash dividend.

Profitability
-111.1%
Return on equity, FY2025
ROE
0.250.50.751-111.1%201920222025
0.250.50.751-111.1%201920222025
Operating margin-32.5%
Net margin-43.5%
Return on assets-24.7%

Each USD of equity lost 111 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
+192.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+115.0%
+192.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.09B
Shares outstanding, FY2025
0.030.09201920222025
0.030.09201920222025
Change, 5 years+101.2%
Change, 10 years—

The share count grew 101% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 327.9M
total assets, end of FY2025
Total assetsUSD 327.9M
EquityUSD 44.7M
CashUSD 190.7M
Current ratio2.01×

Equity funds 14% of total assets.

History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.2
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.0
−0.0
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.0
EPS, diluted $
−0.80
−1.63
−1.21
−0.67
−0.70
−1.76
−2.57
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−111.1
−202.6
−114.0
−52.7
−50.7
−112.7
−136.2
Shares out B
0.09
0.08
0.07
0.06
0.05
0.04
0.03

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed